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Non-histone nuclear factor HMGB1 is phosphorylated
and secreted in colon cancers
Hyun Ju Kang1,2,*, Hanna Lee1,2,*, Hee-Jung Choi1,2, Ju Ho Youn2,3, Jeon-Soo Shin2,3, Yeong Hee Ahn4,
Jong Shin Yoo4, Young-Ki Paik5 and Hoguen Kim1,2
The high mobility group box 1 (HMGB1) protein, a non-histone nuclear factor, is overexpressed and localizes to the
cytoplasm in some cancer cells. However, the mechanism of cytoplasmic HMGB1 transport, extracellular secretion, and its
role in cancer progression is not clear. To simulate the activated state of HMGB1, we mutated serine residues of nuclear
localization signals (NLSs) to glutamic acid and performed transfection assays. We carried out a kinase inhibitor study and
evaluated the cell migration by invasion assay. We showed that phosphorylated HMGB1 localizes in the cytoplasm of
colon cancer cells and also showed the interaction of PKC and HMGB1 by immunoprecipitation analysis. Concurrent
mutations at six serine residues (35, 39, 42, 46, 53, and 181) to glutamic acid induced the nuclear to cytoplasmic transport
of HMGB1, which was detected in the culture medium. We also observed that the secretion of HMGB1 correlated with
increased cancer cell invasiveness. Our results suggest that phosphorylated HMGB1 is transported to the cytoplasm, is
subsequently secreted from the cell, and has a role in tumor progression through the activation of genes related to cell
migration.
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The high mobility group box 1 (HMGB1) protein is one of
several non-histone chromosomal proteins found in eu-
karyotic cells. The protein is typically located in the nucleus
where it binds to minor groove DNA, promotes the assembly
of site-specific DNA-binding factors, and is involved in gene
transcription.1–3 In addition to transcriptional regulation,
HMGB1 has several well-established extracellular roles.
HMGB1 localizes to the cell membrane of neurites for out-
growth.4 It is secreted from activated monocytes, macro-
phages, and NK cells, and acts extracellularly as a
proinflammatory cytokine.5 It is passively secreted by ne-
crotic cells, although not by apoptotic cells, and triggers
inflammation.6,7 Recent studies have shown that the post-
translational modification status of HMGB1 is related to
translocation within cells and secretion by inflammatory
cells, in which it shuttles between the nucleus to the cyto-
plasm through hyperacetylation and phosphorylation in
macrophages, and is monomethylated at Lys42 in neu-
trophils.1,2,8,9 Cytosolic HMGB1 accumulates and is secreted
through a vesicle-mediated secretory pathway in monocytic
cells.10,11
One important extracellular role of HMGB1 is the pro-
motion of cell migration and metastasis.7,12,13 We and others
have previously described the overexpression and cyto-
plasmic localization of HMGB1 in some tumor cells.14,15
These observations raise several additional questions, such as:
(1) How is HMGB1 in tumor cells transported from the
nucleus to the cytoplasm? (2) If HMGB1 is transported to the
cytoplasm and subsequently secreted from cancer cells, which
signal triggers its movement? (3) If HMGB1 is secreted, does
it contribute to cancer cell migration and metastasis?
In this report, we address these questions and show that
phosphorylated HMGB1 localizes in the cytoplasm of colon
cancer cells and is secreted in the extracellular space. We also
showed the secreted HMGB1 induces the MMP pathway and
increases the invasiveness of these cancer cells. These findings
suggest an autocrine and/or paracrine role of HMGB1 in
cancer progression.
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MATERIALS AND METHODS
Cell Lines and Tissue Samples
Cell lines were obtained from the ATCC (American Type
Culture Collection) (http://www.atcc.org) or from the KCLB
(Korean Cell Line Bank) (http://cellbank.snu.ac.kr). Colo205,
DLD-1, HCT116, HCT8, HT29, Ls174T, NCIH508,
NCIH747, SNU-C4, SNU-C2A, and SW480 cells were grown
in the RPMI or DMEM medium supplemented with 10%
fetal bovine serum (Life Technologies Inc., Grand Island, NY,
USA), at 37 1C in the presence of 5% CO2. CCD-18Co and
RKO cells were cultured in the minimal essential medium
supplemented with 10% fetal bovine serum.
Eight colorectal carcinomas and matched normal mucosa
were included in this study. All cases were identified in the
Department of Pathology at the Yonsei University Medical
Center between September 1995 and November 2000. Some
of the fresh specimens were supported by the Liver Cancer
Specimen Bank from the National Research Resource Bank
Program of the Korea Science and Engineering Foundation of
the Ministry of Science and Technology. Authorization for
the use of these tissues for research purposes was obtained
from the Institutional Review Board of the Yonsei University
College of Medicine. To enrich the tumor cell population,
areas with more than 90% tumor cells were selected from
hematoxylin–eosin-stained slides using the cryostat micro-
dissection technique.
Immunohistochemical Analysis
Formalin-fixed and paraffin-embedded tissues were used for
the immunostaining of HMGB1. Deparaffinization and re-
hydration were performed using xylene and alcohol. The
sections were treated with 0.3% hydrogen peroxidase for
3min and blocking antibody for 30min. The antibody
against HMGB1 was at 1:100 (v/v). The avidin–biotin com-
plex methodology was used. The chromogen was diamino-
benzidine and counterstaining was performed with methyl
green.
Protein Extraction
Tumor tissues and matched non-tumorous tissues were
suspended in an ice-cold lysis buffer (50mM Tris (pH 7.4),
1% Triton X-100, 5mM EDTA, 1mM KCl, 140mM NaCl,
2mM MgCl2, 1mM phenylmethylsulfonyl fluoride, 1mM
sodium fluoride, 1% aprotinin, 1 mM leupeptin, and 1mM
sodium orthovanadate) for 15min. Suspensions were soni-
cated for B30 s and centrifuged at 20 000 g for 15min.
Four samples with sufficient material were selected for
nuclear and cytoplasmic protein fractionation. Briefly,
B0.3mg of frozen tissue was added to 1ml of buffer A
(10mM HEPES (N-2-hydroxyethylpiperrazine-N-2-ethane-
sulfonic acid) (pH 7.9), 10mM KCl, 0.1mM EDTA, 0.1mM
EGTA, 1mM dithiothreitol, and 0.5mM phenylmethylsulfo-
nyl fluoride) and homogenized. The cells were allowed to
swell on ice for 15min, after which 50 ml of 10% NP-40 was
added. After vigorous vortex for 10 s, the homogenate was
centrifuged for 30 s. The supernatant was collected and used
for cytoplasmic protein assays. The nuclear pellet was sus-
pended in 100 ml of ice-cold buffer C (20mM HEPES (pH
7.9), 0.4mM NaCl, 1mM EDTA, 1mM EGTA, 1mM dithio-
threitol, and 1mM phenylmethylsulfonyl fluoride) and sha-
ken at 4 1C for 15min. Samples were then centrifuged for
5min, and the supernatant was collected and used for nuclear
protein assays.
Immunoblot and Immunoprecipitation Analysis
Total protein lysate of 20 mg of and 40 mg of cytoplasmic
extracts, and 5 mg of nuclear protein extracts were fractio-
nated by SDS-PAGE. Proteins in the gel were transferred and
blocked with TBS-T containing 5% skim milk. Anti-HMGB1
(BD Biosciences, Franklin Lakes, NJ, USA), anti-hnRNPC
(Santa Cruz Biotechnology, Delaware Avenue, CA, USA),
anti-pan acetylation (Santa Cruz Biotechnology), anti-phos-
phoserine (BD Biosciences), anti-GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) (Trevigen, Gaithersburg, MD,
USA), anti-PKC (Santa Cruz Biotechnology), and anti-a-
Tubulin (Oncogene, Cambridge, MA, USA) were diluted
1:5000 in the blocking buffer and incubated for 1 h at room
temperature. Membranes were washed and then incubated
for 1 h with HRP-conjugated secondary antibody (Santa Cruz
Biotechnology), washed, and developed with ECL-Plus
(Amersham Pharmacia Biotech, Uppsala, Sweden). For im-
munoprecipitation experiments, 500 mg of tissue lysates
were pre-cleared with PBS and gently rocked on an orbital
shaker with anti-HMGB1 (BD Biosciences) at 4 1C. The
immune complexes were collected by centrifugation and
boiled to dissociate the immunocomplexes from the beads.
The beads were collected by centrifugation and protein se-
paration was performed by SDS-PAGE with the supernatant
fraction.
2-Dimensional Electrophoresis (2DE) Immunoblot
Analysis
Colorectal carcinoma and matched normal tissues were
suspended in the sample buffer (40mM Tris, 7M urea, 2M
thiourea, 4% CHAPS, and 100mM 1, 4-dithioerythritol)
and in a protease inhibitor cocktail (Roche, Mannheim,
Germany). Suspensions were sonicated for B30 s and
centrifuged at 100 000 g for 45min. One milligram of total
protein was used for each 2DE analysis. Aliquots of proteins
in the sample buffer were applied onto immobilized pH 3–10
non-linear gradient strips (Amersham Pharmacia Biotech),
and isoelectric focusing was conducted at 100 000 Vh. 2DE
was performed in 9–16% linear gradient polyacrylamide gels
(18 cm 20 cm 1.5mm) as previously described,16 trans-
ferred into PVDF membranes, and subsequently blocked
in TBS-T containing 5% skim milk. Anti-HMGB1 (BD
Biosciences) was diluted 1:5000 in the blocking buffer and
incubated with the membranes for 1 h at room temperature.
After washing, the membranes were incubated for 1 h
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with HRP-conjugated secondary antibody (Santa Cruz
Biotechnology), washed, and developed with ECL-Plus
(Amersham Pharmacia Biotech).
Vector Construction and Transfection
We performed transfection assays with the following four
vectors (kindly provided by Dr J-S Shin, Department of
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Microbiology, Yonsei University College of Medicine, Korea):
(1) EGFPN1, used as a control; (2) nuclear localization signal
(NLS)-WT, containing wild-type HMGB1; (3) NLS(1,2)-AT,
containing HMGB1 sequence in which the six serine residues
in the NLS 1 and 2 regions were mutated to alanine for the
inhibition of HMGB1 phosphorylation; and (4) NLS(1,2)-
ET, containing HMGB1 sequence in which the six serine
residues in the NLS 1 and 2 regions were mutated to glutamic
acid for simulation of phosphorylated HMGB1.17
Six vectors, namely NLS-35ET, NLS-39ET, NLS-42ET,
NLS-46ET, NLS-53ET, and NLS-181ET that contained serine
to glutamic acid mutations in the NLS1 and NLS2 regions
were constructed. One vector (NLS(1)-ET) contained serine
to glutamic acid mutations of all five serine residues in the
NLS1 region. An additional vector (NLS(1)-AT) contained
serine to alanine mutations in all five serine residues.
All the vectors were constructed using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA),
and sequences were confirmed by direct sequencing analysis
(Figure 1a).
HCT116 cell and CCD-18Co were transiently transfected
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
with the constructed plasmid in LabTek II chambers (Nal-
gene, Waltham, MA, USA) or in a 60-mm tissue culture
plate. Cells were observed or harvested 2 days later.
Immunofluorescence Imaging Analysis
Cells were cultured in LabTek II chambers (Nalgene) and
fixed in 10% paraformaldehyde in PBS for 10min at room
temperature. The cells were then washed with PBS and in-
cubated for 5min at 4 1C with the permeabilization buffer
containing 0.1% Triton X-100 in PBS. Samples were blocked
with 2% BSA in PBS for 30min and incubated with rabbit
anti-HMGB1 for 1 h at room temperature. After three washes
with 0.2% BSA in PBS, Alexa Fluor 488 secondary antibody
(Invitrogen) was added. The mounting medium containing
propidium iodide (Vector Laboratories, Burlingame, CA,
USA) was used. Fluorescently labeled cells were observed
using the Zeiss LSM 510 confocal microscope (Carl Zeiss,
Germany), and images were processed using the LSM 5
Image Examiner software.
Drug Treatment
HCT116 cell lines were treated with kinase inhibitors
Quercetin, Tamoxifen, Myricetin (Calbiochem, Dermstadt,
Germany), Rottlerin (Sigma-Aldrich, St Louis, MO, USA),
and chromosome region maintenance 1 (CRM1)-mediated
active export inhibitor Leptomycine B (Sigma-Aldrich). We
treated with Myricetin at 3mM or 10 mM, Quercetin at
20 mM, Tamoxifen at 6 mM, and Rottlerin at 10 mM. All drugs
were dissolved in either distilled water or DMSO (dimethyl
sulfoxide) and were added to the culture medium in volumes
not exceeding 0.5% of the total culture medium volume.
Invasion Assay
The Cell Invasion Assay Kit (Chemicon International,
Temecula, CA, USA) was used according to the manu-
facturer’s instructions. Briefly, the ECM layer was rehydrated
for 1–2 h at room temperature using the serum-free medium.
A volume of 500 ml of the medium containing 10% fetal
bovine serum was added to the lower chamber, and prepared
cell suspension in the serum-free medium was added to the
upper chamber. Cells were incubated for 40 h at 37 1C in the
presence of 5% CO2. Non-invading cells were removed from
the upper chamber and invasive cells on the lower surface of
the membrane were stained for 20min. Invasiveness quan-
tities were measured by dissolving stained cells in 10% acetic
acid; a consistent amount of the dye–solute mixture was
transferred into a 96-well plate for colorimetric reading of
OD at 560 nm. Each experiment was performed in triplicate.
RESULTS
Overexpression and Cytoplasmic Localization of HMGB1
in Colon Cancer Cells
We first examined the amount of HMGB1 in eight colon
cancer tissue samples and in normal mucosal tissues by
immunoblot analysis. We found that HMGB1 was over-
expressed in all colon cancer tissues that were tested. We also
observed strong HMGB1 expression in 12 colon cancer cell
lines, despite the variability between samples (Figure 2a). We
then examined the level of nuclear and cytoplasmic HMGB1
by the fractionation of nuclear and cytoplasmic proteins in
four colon cancer tissues and normal mucosal tissues. The
normal colonic fibroblast cell line, CCD-18Co, was used as a
control. Strong HMGB1 expression was observed in both the
nucleus and the cytoplasm in all four colorectal carcinomas
and in four colon cancer cell lines. The amount of nuclear
HMGB1 in cancer cells, normal tissues, and normal fibroblast
cell lines was not significantly different. However, cyto-
plasmic HMGB1 was absent or was present at low levels in
normal tissues and normal fibroblast cell lines (Figure 2b and
Figure 3), whereas cytoplasmic HMGB1 was found at high
levels in tumor cells.
Figure 1 Phosphorylation of serines 35, 39, and 42 is critical for cytoplasmic localization of HMGB1. (a) Schematic diagram of the HMGB1 gene structure and
constructed vectors. HMGB1 consists of two DNA-binding domains, the HMG boxes A and B, and an acidic C-terminal domain. The A box and B box both
contain nuclear localization signals (NLSs) NLS1, which includes amino acids 28–53, and NLS2, which includes amino acids 179–185. A description of each
vector can be found in the text. (b) Localization of HMGB1 in HCT116 cells transfected with NLS-WT, NLS(1,2)-AT, or NLS(1,2)-ET. Cytoplasmic HMGB1 was
evident in the cell lines transfected with NLS-WT and NLS(1,2)-ET. (c) Cytoplamic HMGB1 (arrows) is found in the HCT116 cells transfected with NLS(1)-ET
(vector for which all five serine residues in the NLS1 region were mutated to glutamic acid), NLS-35ET, NLS-39ET, and NLS-42ET (containing a serine to
glutamic acid mutation at the indicated residue; Figure a).
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Identification of Cytoplasmic Phosphorylated HMGB1 in
Cancer Cells
As we observed that the intracellular distribution of HMGB1
differs between tumor and normal mucosa, we next com-
pared the modification status of HMGB1 in these samples by
2DE and an immunoblot analysis using an HMGB1 antibody.
Some spots with strong intensities in colon cancer samples
had more acidic isoeletric points compared with those from
the normal mucosa (Figure 4a). We next used prediction
servers (http://www.cbs.dtu.dk/services/NetPhos/ and http://
www.cbs.dtu.dk/services/NetAcet/) to predict the modifica-
tion status and found that phosphorylation and acetylation
may occur in HMGB1. To validate any potential phosphor-
ylation and acetylation modifications in HMGB1, we per-
formed immunoprecipitation assays using protein lysates and
an HMGB1 antibody followed by immunoblot analysis using
antibodies against phosphorylated and acetylated proteins.
We found that cells from both normal mucosa and cancer
tissues contained acetylated HMGB1, but phosphorylated
HMGB1 was only present in cancer cells (Figure 4b).
Cytoplasmic Transport of HMGB1 is Related to the
Modification of Serine Residues in the NLS Sequence
Some reports have previously suggested that modified
HMGB1 is related to its cytoplasmic transport and secretion
in inflammatory cells. In this study, we hypothesized that
phosphorylation of HMGB1 is required for cytoplasmic
transport in cancer cells. To test this hypothesis, we per-
formed transfection assays with control and modified
HMGB1 vectors to simulate the phosphorylation state of
Figure 2 Overexpression and nuclear and cytoplasmic localization of HMGB1 in colon cancer cells. (a) HMGB1 expression in total protein lysates from four
colon cancer samples, matched normal mucosal tissue samples, and 12 colon cancer cell lines. N, total protein lysate from the normal colon tissue; T, total
protein lysate from the cancer tissue. (b) Analysis of HMGB1 expression in the nuclear and cytoplasmic protein fractions from four colon cancer tissues and
five cell lines. Anti-hnRNPC was used for a nuclear protein control. Anti-tubulin was used for a cytoplasmic protein control. Nu, nuclear protein lysates;
Cy, cytoplasmic protein lysates.
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Figure 3 Localization of HMGB1 in CCD-18Co (normal), HCT116 (cancerous) cell lines, normal colonic mucosa, and colon cancer tissues. Both nuclear and
cytoplasmic localizations (arrow) were evident in the HCT116 cell line. In normal mucosa, only mucosa localization was evident in colonic epithelial cells.
In cancer cells, both nuclear and cytoplasmic localization were evident.
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translocated HMGB1. We mutated serine residues within
both of the nuclear localization signals (NLSs) in HMGB1 to
glutamic acid to simulate the phosphorylation status of the
protein. We used the following four vectors in this experi-
ment: (1) EGFPN1, used as a negative control; (2) NLS-WT,
contains wild-type HMGB1 for overexpression of HMGB1;
(3) NLS(1,2)-AT, contains HMGB1 sequence in which six
serine residues in NLS 1 and 2 were mutated to alanine
for the inhibition of HMGB1 phosphorylation; and (4)
NLS(1,2)-ET, contains HMGB1 sequence in which the six
serine residues in NLS 1 and 2 were mutated to glutamic acid
for the simulation of phosphorylated HMGB1 (Figure 1a).
When CCD-18Co cells were transfected with NLS(1,2)-AT or
NLS-WT, HMGB1 was observed only in the nucleus. In
contrast, high levels of HMGB1 were observed in the cyto-
plasm of CCD-18Co cells transfected with the NLS(1,2)-ET
vector (Supplementary Figure 1). In similar experiments
using the colon cancer cell line HCT116, both nuclear and
cytoplasmic HMGB1 was identified after transfection with
NLS-WT, and HMGB1 was exclusively located in the nucleus
after transfection with the NLS(1,2)-AT vector. In contrast,
the majority of HMGB1 was located in the cytoplasm of
HCT116 cells transfected with the NLS(1,2)-ET vector (Fig-
ure 1b). These results were confirmed by the immunoblot of
nuclear and cytoplasmic lysates (data not shown).
Phosphorylation of Serines 35, 39, and 42 are Critical for
Nucleus To Cytoplasmic HMGB1 Transport
To identify which of the six serine residues in the NLS 1 and
2 regions is critical for HMGB1 transport from the nucleus
Figure 4 Identification of cytoplasmic phosphorylated HMGB1 in cancer cells. (a) 2DE immunoblot analysis with anti-HMGB1. Some HMGB1 spots with
strong intensity in colon cancers show more acidic isoeletric points compared with normal mucosa (arrows). (b) Immunoprecipitation and immunoblot
analysis with anti-acetylation and anti-phosphoserine. Both normal mucosa and cancer tissues contained acetylated HMGB1, but phosphorylated HMGB1
was only present in cancerous cells.
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to the cytoplasm, we constructed six HMGB1 vectors (NLS-
35ET, NLS-39ET, NLS-42ET, NLS-46ET, NLS-53ET, and
NLS-181ET), each containing a serine to glutamic acid mu-
tation at the indicated residue (Figure 1a). We also con-
structed one vector (NLS(1)-ET) for which all five serine
residues in the NLS1 region were mutated to glutamic acid.
The matched vector NLS(1)-AT was also constructed, where
all five serine residues were converted to alanine. In this
transfection study, we observed that only cells transfected
with NLS(1)-ET, NLS-35ET, NLS-39ET, and NLS-42ET
showed increased HMGB1 transport from the nucleus to the
cytoplasm as compared with cells transfected with the other
three vectors (Figure 1c), suggesting that serine residues at
35, 39, and 42 are important for HMGB1 transport.
HMGB1 Phosphorylation is Inhibited by Kinase
Inhibitors
To identify factors responsible for HMGB1 phosphorylation,
we used the NetPhosK 1.0 server (http://www.cbs.dtu.dk/
services/NetPhosK/) to identify kinases that could potentially
bind to and induce the phosphorylation of HMGB1. We
identified casein kinase 1 (CK1) and PKC as possible can-
didates. Thereafter, we carried out a kinase inhibitor study to
test which factor was involved in HMGB1 phosphorylation.
We used Quercetin to inhibit CK1, and Tamoxifen, Myr-
icetin, and Rottlerin to inhibit PKC. We also used Myricetin
at both 3 and 10 mM, as it has been reported to inhibit CK1
or PKC at low or high concentrations, respectively. The dis-
tribution of HMGB1 did not change in HCT116 cells treated
with Quercetin or with 3mM of Myricetin, indicating that
CK1 was not involved in HMGB1 translocation. In contrast,
HMGB1 expression in the cytoplasm was significantly
decreased in cells treated with Tamoxifen and Rottlerin
(Figure 5a). Decreased cytoplasmic expression of HMGB1
was also observed in cells treated with 10 mM of Myricetin.
The requirement for PKC was validated by im-
munoprecipitation analysis to test of co-interaction between
PKC and HMGB1 (Figure 5b). These findings indicate that
PKC signaling is involved in the cytoplasmic translocation of
HMGB1 in colorectal cancer cells.
Figure 5 Cytoplasmic HMGB1 is decreased after treatment of kinase inhibitor. (a) The distribution of HMGB1 did not change with treatment of CK1
inhibitors, Quercetin or low dose (3 mM) of Myricetin treatment. HMGB1 expression in the cytoplasm is significantly decreased in treatment of PKC inhibitors,
Tamoxifen, and Rottlerin treatment in HCT116 cells. Decreased cytoplasmic expression was also found in a high dose (10 mM) of Myricetin treatment, one of
PKC inhibitor. (b) Verification of the binding of PKC and HMGB1 by immunoprecipitation analysis in HCT116 cell line. Binding of PKC and HMGB1 was noted.
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HMGB1 is Unidirectionally Transported from the
Nucleus to the Cytoplasm
HMGB1 is a small molecule and has the potential to migrate
from the nucleus to the cytoplasm by simple diffusion across
nuclear pores. To test whether the translocation of HMGB1
from the nucleus to the cytoplasm is unidirectional in a
CRM1-dependent manner, or whether it is bidirectional by
simple diffusion, we treated HCT116 cells with Leptomycine
B, an inhibitor of CRM1-mediated active export. We found
that endogenous cytoplasmic HMGB1 was decreased mark-
edly after treatment of Leptomycine B, indicating that the
cytoplasmic translocation of HMGB1 was unidirectional and
conducted through active transport (data not shown).
Secretion of HMGB1 is Related to Increased Tumor Cell
Invasiveness
The results described above predict that modified HMGB1 is
secreted into the extracellular space. To confirm this idea, we
measured the amount of HMGB1 by immunoblot in the
culture medium from cells transfected with the vectors de-
scribed above. A relatively large amount of HMGB1 was
detected in the culture medium of HCT116 cells transfected
with the NLS-WT or NLS(1,2)-ET vector. In contrast, scant
amounts of HMGB1 were noted in the medium from cells
transfected with the NLS(1,2)-AT vector (Figure 6a). To
verify the phosphorylation status of HMGB1 in the culture
medium, we performed immunoprecipitation experiments
using media protein and an HMGB1 antibody, followed by
immunoblot analysis using antibodies against phosphory-
lated proteins. We found that phosphorylated HMGB1 was
present in the culture medium of cancer cells (Figure 6b).
These findings indicate that phosphorylated HMGB1 is
transported to the cytoplasm and subsequently secreted into
the extracellular space.
To extend these observations to tumor cell invasiveness, we
next performed the invasion assay using tissue culture plate
containing an 8-mm pore size polycarbonate membrane,
which blocked non-invasive cells from migrating through.
Invasive cells, on the other hand, migrate through the layer
and cling to the bottom of the polycarbonate membrane. We
found that the invasiveness was increased markedly in cells
transfected with NLS(1,2)-ET and slightly increased in cells
transfected with NLS-WT. Cells transfected with NLS(1,2)-
AT or the control vector showed low invasion activity com-
pared with cells transfected with NLS-WT or NLS(1,2)-ET
(Figure 6c). Especially, we observed that the invasiveness was
increased in cells transfected with NLS(1)-ET, NLS-35ET,
NLS-39ET, and NLS-42ET as compared with cells transfected
with the other three vectors (Figure 6c). To ascertain the role
of secreted HMGB1, we treated cells with recombinant
HMGB1 by including it in the culture medium, and found
that invasiveness was increased markedly in HCT116 cells
(Figure 6d). These findings indicate that phosphorylated
HMGB1 is directly related to cell invasion capacity. We also
constructed one vector (NLS(1)-ET) in which all five serine
residues in the NLS1 region were mutated to glutamic acid.
The matched vector NLS(1)-AT was also constructed, where
all five serine residues were converted to alanine. In this
transfection study, we observed that only cells transfected
with NLS(1)-ET, NLS-35ET, NLS-39ET, and NLS-42ET
showed increased HMGB1 transport from the nucleus to the
cytoplasm as compared with cells transfected with the other
three vectors (Figure 1c), suggesting that serine residues at
35, 39, and 42 are important for HMGB1 transport.
DISCUSSION
In this study, we showed the overexpression of HMGB1 in
cancer cells, cytoplasmic transport of HMGB1, the presence
of extracellular HMGB1, HMGB1 phosphorylation, activa-
tion of the MMP pathway, and increased cell invasion after
transfection of activated HMGB1. These findings suggest that
HMGB1 indeed has a role in the ability of cancer cells to
invade surrounding tissue and metastasis.
One of the important roles of HMGB1 is cell migration,
and metastasis in cancer cells involves the activation of RAGE
and the MMP pathway.2,12,18,19 It has been proposed that
secreted HMGB1 from both inflammatory and necrotic cells
has a role in this signal transduction event.19–23 In this study,
we showed that endogenous HMGB1 can be secreted into the
extracellular space, where it can bind to RAGE and activate
the MMP pathway. Our novel finding that endogenous
HMGB1 can cause aberrant signaling events in cancer cells
partially explains the early phase of cancer metastasis, which
is a complicated and multistep process. Little is known about
the mechanism by which cancer cells acquire invasion and
cell migration ability. In this study, we suggest that the signals
required for metastasis can be initiated by the cancer cell itself
through autocrine and/or paracrine activation by the secreted
HMGB1.
Our data suggest that the nuclear and/or cytosolic dis-
tribution of HMGB1 is caused by protein phosphorylation.
We propose that the cytoplasmic transport of HMGB1 is the
result of its phosphorylation. It has been shown that phos-
phorylation of HMGB1 leads to more negatively charged
groups on the protein, reducing its DNA-binding activity by
up to 10-fold.24,25 Therefore, we suggest that the reduced
DNA-binding affinity of HMGB1 might be related to its
cytoplasmic transport. We modified the serine residues in
two NLS regions of HMGB1 to glutamic acid (NLS(1,2)-ET)
for simulating phosphorylation and to alanine (NLS(1,2)-
AT) for preventing phosphorylation. Cells transfected with
the NLS(1,2)-ET vector showed increased cytoplasmic
HMGB1 transport, whereas HMGB1 was retained in the
nucleus in cells transfected with the NLS(1,2)-AT vector.
These findings indicate that the negatively charged status
of HMGB1 was directly related to cytoplasmic transport.
Moreover, our CRM1 inhibition study showed a marked
reduction of endogenous cytoplasmic HMGB1. This indi-
cates that HMGB1 is translocated from the nucleus to the
cytoplasm by active transport rather than by simple diffusion,
HMGB1 secretion in colon cancer cells
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and implies that HMGB1 phosphorylation occurs in the
nucleus. These findings also suggest that a signal transduc-
tion pathway activated in these cancer cells regulates the
translocation of endogenous HMGB1.
Our results suggest that HMGB1 phosphorylation might
be induced by PKC. In addition, the phosphorylation of
serines 35, 39, and 42 of the NLS1 region in HMGB1 is
critical for HMGB1 transport into the cytoplasm, and these
serine residues are consistent with the predicted PKC binding
site. The PKC family consists of at least 12 serine–threonine
kinases that are classified into three major groups,26,27 and
their expression level was variable according to cancer type.
The most important and well-known cancer-related targets of
PKC are Erk1/2, glycogen synthase kinase-3 beta (GSK-3b),
Figure 6 Extracellular HMGB1 promote cell invasion. (a) Immunoblot analysis of HMGB1 from the culture medium of HCT116 cells transfected with NLS-WT,
NLS(1,2)-AT, or NLS(1,2)-ET vectors. Secreted HMGB1 was evident in the cell lines transfected with NLS-WT and NLS(1,2)-ET. (b) Immunoprecipitation of
media protein lysates using HMGB1 antibody and immunoblot using antibodies against phosphorylated proteins. Similar amount of endogenous
phosphorylated HMGB1 was found in all of four cell lines transfected with different vectors. (c) Invasion activity are increased in HCT116 cells transfected
with NLS(1,2)-ET vector than in cells transfected with other forms of vectors (NLS-WT, NLS(1,2)-AT and EGFPN1). Especially, the invasiveness was increased in
cells transfected with NLS(1)-ET, NLS-35ET, NLS-39ET, and NLS-42ET as compared with cells transfected with the other three vectors (NLS-46ET, NLS-53ET,
and NLS(1)-AT). (d) Treatment of recombinant HMGB1 protein in the culture media showed increased invasiveness of tumor cells.
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nuclear factor kappa B (NFkB), and P-glycoprotein.28,29
Previous reports have shown that the biological functions of
PKC are mostly linked to events occurring at the plasma
membrane or in the cytoplasm. PKC isoforms are thought to
reside in the cytoplasm in an inactive state, translocated to
the plasma membrane after stimulation, and become acti-
vated in the presence of specific co-factors.30–33 However,
some reports have indicated that PKC isoforms are located in
the nucleus or are translocated to the nucleus. Similarly,
other reports have suggested a direct relationship between
nuclear PKC and tumorigenesis,34–37 although the regulatory
role of nuclear PKC in cancer is not completely under-
stood.34–39 In this study, we showed that HMGB1 interacted
with PKC. Future functional analysis for the relationship
between the specific type of PKC and nuclear phosphoryla-
tion might provide valuable information about the role of
HMGB1 in tumor progression and invasion. In addition,
HMGB1 indeed has a ‘double-edged role,’ such as interacting
with infiltrating RAGE expressing monocytes and lympho-
cytes, besides possibly activating other innate receptors, TLR4
and TLR2.40–43
In conclusion, we showed that a portion of nuclear
HMGB1 is phosphorylated in colon cancers and that phos-
phorylated HMGB1 is believed to be involved in the extra-
cellular secretion. Further study is required to elucidate that
the secreted HMGB1 activates the genes involved in tumor
invasion and migration of cancer cells. Phosphorylated
HMGB1 then induces migration of the cancer cells. These
findings suggest that cancer cells can acquire the ability to
invade surrounding tissues and to metastasize through the
activation of endogenous nuclear HMGB1.
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